Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
BigHat Biosciences develops antibody and protein therapeutics using machine learning, synthetic biology, and automated experimentation.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Circle Pharma is a biotechnology company creating bioavailable macrocyclic peptide therapeutics that target protein-protein interactions.
Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.
QurCan Therapeutics (formerly known as Nanology Labs) is a biotech company developing next-generation nanoparticles for gene/chemotherapy.
Thatch provides a health benefits platform that lets employers set health budgets and employees choose insurance and healthcare services.
ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers.
UpDoc is a technology-enabled services company that offers the first-ever proprietary conversational AI platform for autonomous.
Cloverleaf Bio develops an RNA therapeutic platform for oncology.
Moonwalk Biosciences operates a genomic medicine company that aims to provide a new class of precision epigenetic medications.
Superluminal Medicines develops small-molecule therapeutics using AI, biology, and chemistry.
Leal Therapeutics develops novel therapeutics for patients.
Ratio Therapeutics is a clinical-phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.
Oura designs and develops wearable rings that track sleep and performance metrics for health and wellness monitoring.
AdvanCell develops targeted alpha radiopharmaceutical therapies for cancer and supports their development and manufacturing.
Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins
TRIMTECH Therapeutics treats inflammatory and persistent CNS conditions by focusing on the elimination of harmful proteins.
Laverock Therapeutics is a biotechnology company developing programmable gene control technologies for advanced cell and gene therapies.
Remedium Bio is a gene therapy company focused on the development of highly innovative treatments for a broad range of diseases.
LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
Eli Lilly has invested in 169 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Eli Lilly's top investment sectors include Biotechnology, Medical, Therapeutics, Life Science, Pharmaceutical. The firm invests across 25 different industry categories.
Among tracked funding rounds, Oura received $900.0M in a Corporate Round round. Eli Lilly's total known invested capital is $11.1B.
Eli Lilly's average investment size is $69.2M across its portfolio of 169 companies.
Recent Eli Lilly portfolio additions include BigHat Biosciences, Orbis Medicines, Circle Pharma, Beta Bionics, QurCan Therapeutics Inc.. These companies were founded in 2020 or later.